Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia
- PMID: 20181958
- PMCID: PMC2857799
- DOI: 10.1093/jnci/djq043
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia
Abstract
Background: Chronic immune stimulation appears to be associated with lymphoplasmacytic lymphoma (LPL)-Waldenström macroglobulinemia (WM); however, available information is sparse. We conducted, to our knowledge, the most comprehensive study to date to evaluate associations between a personal or family history of many immune-related and/or inflammatory disorders and the subsequent risk of LPL-WM.
Methods: We used Swedish population-based registries to identify 2470 case patients with LPL-WM, 9698 matched control subjects, and almost 30 000 first-degree relatives of either case patients or control subjects. We evaluated a wide range of autoimmune, infectious, allergic, and inflammatory conditions. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for each condition by use of logistic regression.
Results: An increased risk of LPL-WM was associated with a personal history of the following autoimmune diseases: systemic sclerosis (OR = 4.7, 95% CI = 1.4 to 15.3), Sjögren syndrome (OR = 12.1, 95% CI = 3.3 to 45.0), autoimmune hemolytic anemia (OR = 24.2, 95% CI = 5.4 to 108.2), polymyalgia rheumatica (OR = 2.9, 95% CI = 1.6 to 5.2), and giant cell arteritis (OR = 8.3, 95% CI = 2.1 to 33.1). An increased risk of LPL-WM was associated with a personal history of the following infectious diseases: pneumonia (OR = 1.4, 95% CI = 1.1 to 1.7), septicemia (OR = 2.4, 95% CI = 1.2 to 4.3), pyelonephritis (OR = 1.7, 95% CI = 1.1 to 2.5), sinusitis (OR = 2.7, 95% CI = 1.4 to 4.9), herpes zoster (OR = 3.4, 95% CI = 2.0 to 5.6), and influenza (OR = 2.9, 95% CI = 1.7 to 5.0). An increased risk of LPL-WM was associated with a family history of the following autoimmune or infectious diseases: Sjögren syndrome (OR = 5.0, 95% CI = 2.1 to 12.0), autoimmune hemolytic anemia (OR = 3.8, 95% CI = 1.1 to 13.2), Guillain-Barré syndrome (OR = 4.1, 95% CI = 1.8 to 9.4), cytomegalovirus (OR = 2.7, 95% CI = 1.4 to 5.3), gingivitis and periodontitis (OR = 1.9, 95% CI = 1.3 to 2.7), and chronic prostatitis (OR = 4.3, 95% CI = 1.7 to 11.1).
Conclusions: Personal history of certain immune-related and/or infectious conditions was strongly associated with increased risk of LPL-WM. The association of both personal and family history of Sjögren syndrome and autoimmune hemolytic anemia with risk of LPL-WM indicates the potential for shared susceptibility for these conditions.
Similar articles
-
Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.J Natl Cancer Inst Monogr. 2014 Aug;2014(48):87-97. doi: 10.1093/jncimonographs/lgu002. J Natl Cancer Inst Monogr. 2014. PMID: 25174029 Free PMC article.
-
Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.J Thromb Haemost. 2014 Nov;12(11):1816-21. doi: 10.1111/jth.12724. Epub 2014 Oct 6. J Thromb Haemost. 2014. PMID: 25196979
-
Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia.Br J Haematol. 2014 Mar;164(5):653-8. doi: 10.1111/bjh.12671. Epub 2013 Nov 26. Br J Haematol. 2014. PMID: 24528127 Free PMC article.
-
Autoimmune manifestations in patients with Waldenström macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):456-9. doi: 10.1016/j.clml.2014.04.009. Epub 2014 Jun 10. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25022601 Review.
-
Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.Acta Haematol. 2012;127(3):173-7. doi: 10.1159/000335618. Epub 2012 Feb 3. Acta Haematol. 2012. PMID: 22310551 Free PMC article. Review.
Cited by
-
Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.BMC Cancer. 2020 Jul 3;20(1):623. doi: 10.1186/s12885-020-07120-9. BMC Cancer. 2020. PMID: 32620091 Free PMC article.
-
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.Eur J Haematol. 2021 Mar;106(3):380-388. doi: 10.1111/ejh.13563. Epub 2020 Dec 28. Eur J Haematol. 2021. PMID: 33295006 Free PMC article.
-
Blurry Vision as a Presentation of Waldenström's Macroglobulinemia: A Case Report With Review of Current Management.J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096211052187. doi: 10.1177/23247096211052187. J Investig Med High Impact Case Rep. 2022. PMID: 35258381 Free PMC article.
-
Merkel cell carcinoma: a population-based study on mortality and the association with other cancers.Cancer Causes Control. 2011 Nov;22(11):1521-7. doi: 10.1007/s10552-011-9826-4. Epub 2011 Aug 20. Cancer Causes Control. 2011. PMID: 21858506 Free PMC article.
-
Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.J Natl Cancer Inst Monogr. 2014 Aug;2014(48):87-97. doi: 10.1093/jncimonographs/lgu002. J Natl Cancer Inst Monogr. 2014. PMID: 25174029 Free PMC article.
References
-
- Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. - PubMed
-
- Björkholm M. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. In: Canellos G, Lister A, Young B, editors. The Lymphomas. 2nd ed. Philadelphia, PA: W.B. Saunders; 2006. pp. 374–380.
-
- Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF., Jr Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82(6):1078–1081. - PubMed
-
- Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood. 1993;82(10):3148–3150. - PubMed
-
- Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214–226. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical